Jeff Aronin's Emalex raises $35M Series C; British protein degradation biotech emerges from stealth
Jeff Aronin has a new raise in place for one of his portfolio companies.
Emalex Biosciences is banking a $35 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
